T1	intervention 61 91	adjuvant trastuzumab emtansine
T2	control 99 110	trastuzumab
T3	intervention-participants 1221 1224	743
T4	control-participants 1247 1250	743
T5	outcome 1566 1582	role functioning
T6	iv-bin-percent 1584 1587	49%
T7	cv-bin-percent 1591 1594	41%
T8	outcome 1597 1610	appetite loss
T9	iv-bin-percent 1612 1615	38%
T10	cv-bin-percent 1619 1622	28%
T11	outcome 1625 1637	constipation
T12	iv-bin-percent 1639 1642	47%
T13	cv-bin-percent 1646 1649	38%
T14	outcome 1652 1659	fatigue
T15	iv-bin-percent 1661 1664	66%
T16	cv-bin-percent 1668 1671	60%
T17	outcome 1674 1689	nausea/vomiting
T18	iv-bin-percent 1691 1694	39%
T19	cv-bin-percent 1698 1701	30%
T20	outcome 1708 1737	systemic therapy side effects
T21	iv-bin-percent 1739 1742	49%
T22	cv-bin-percent 1746 1749	36%
T23	outcome 1842 1858	role functioning
T24	outcome 1801 1818	6-month follow-up
T25	iv-bin-percent 1860 1863	23%
T26	cv-bin-percent 1867 1870	16%
T27	eligibility 547 729	Patients who received taxane- and trastuzumab-containing neoadjuvant therapy (with/without anthracyclines) and had residual invasive disease (breast and/or axillary nodes) at surgery
